SkyePharma

making good drugs better

Michael Ashton
Chief Executive

SG Cowen

24th Annual Health Care Conference

11 March 2004

NASDAQ:SKYE LSE:SKP
www.skyepharma.com
UK tel: +44 (0)207 491 1777
US tel: +1 (212) 753 5780

Legal statement

This presentation does not constitute or form part of any offer for sale or subscription or solicitation of any offer to buy or subscribe for any securities in SkyePharma PLC nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. This presentation is only being distributed to persons who fall within Article 8 of the Financial Services Act 1986 (Investment Advertisements) (Exemptions) (No 2) Order 1997 or Article 11(3) of the Financial Services Act 1986 (Investment Advertisements) (Exemptions) Order 1996, as amended.

This presentation includes certain forward-looking statements with respect to certain development projects, potential collaborative partnerships, results of operations and certain plans and objectives of SkyePharma including, in particular, the statements regarding potential sales revenues from Paxil CR™, targeted sales revenues from other products both currently marketed and under development, possible launch dates for new products, and our revenue and profit guidance for the 2003 financial year. By their very nature forward-looking statements involve risk and uncertainty that could cause actual results and developments to differ materially from those expressed or implied. The significant risks related to SkyePharma's business which could cause our actual results and developments to differ materially from those forward-looking statements are discussed in SkyePharma's SEC filings under the caption "Risk Factors".

SkyePharma reports under UK GAAP. Where US dollar equivalents have been provided for convenience in this presentation, a fixed exchange rate of $1.84 = £1 has been used throughout. **These dollar equivalent numbers do not imply restatement from UK GAAP to US GAAP**.

This presentation was updated on 10th March 2004

SkyePharma in brief

- UK-domiciled speciality pharmaceutical company
- originally founded 1983, IPO 1996
- listed London (SKP), New York (ADR, SKYE)
- market capitalisation £400/$745 mn

  (10 Mar: 65p/share $12.50/ADR)

Drug delivery – making good drugs better

We normally work on drugs already proven safe and effective

- **low risk of clinical failure**
- **short development times**
- **low development cost**

We rely on partners for sales and marketing

Two business models

	Contract drug delivery project *Example: Paxil CR™*	**Self-funded project** *Example: DepoMorphine™*
Risk	Low	Medium *NB much lower than for a NCE*
Return	Low	High
Out-licence stage	Start of project	Late-stage clinical trials
R&D costs	Partner (reimburses SkyePharma) $5-10 mn	SkyePharma $25-50 mn
Milestone payments	Modest <$10 mn	High $50-100 mn
Royalty rate	Low 3-7%	High 20-50%

A transforming business



Nine approved products

FDA approvals validate three of our five delivery technologies

Foradil® Certihaler™ "approvable" letter (Oct '03) validates fourth (pulmonary)

Strong clinical pipeline

2 Filed, 4 x Phase III, 3 x Phase II

Changing **quality of earnings:**

Royalty income replacing milestones as main revenue source, driven by

Now: Paxil CR™, Xatral® OD/Uroxatral®, Solaraze®, DepoCyt®

Future: Foradil® Certihaler™, DepoMorphine™, HFA-formoterol, Propofol IDD-D™

Global infrastructure



FDA/EMA approved manufacturing facilities

>400 staff worldwide of which 50% scientists / clinical staff

Global business development coverage

Two lead marketed products

Paxil CR™ (GlaxoSmithKline)

Xatral® OD / Uroxatral® (Sanofi-Synthélabo)

Paxil CR™

GlaxoSmithKline

Geomatrix™ oral formulation of GSK's SSRI antidepressant Paxil® (paroxetine)

Paxil CR™ is clinically differentiated from Paxil®

- reduced incidence of nausea leads to improved compliance, better efficacy

GSK has invested to develop new indications for Paxil CR™

- depression — approved 1999
- panic disorder — approved 2001
- social anxiety disorder — approved 2003
- PMDD (Paxil® never approved for this indication):
  - continuous — approved Sep '03
  - intermittent — approved Feb '04

Paxil CR™ – clinically differentiated





Source: Golden et al., J. Clin. Psych. (July 2002)



Benefits confirmed in practice

Database study examined 80,000 US patients in managed care treated for depression

Patients taking Paxil CR™ were **28% less likely to discontinue therapy** than patients taking competing immediate-release SSRIs

Managed Care Interface (Dec 2003)

Paxil CR™ – defending the Paxil® franchise

Paxil CR™ has captured ~8% of the US SSRI antidepressant prescription market

- **first US generic competition for Paxil® started 8 September '03**
  - a prescription for Paxil CR™ cannot be substituted with generic paroxetine…
  - …but some indirect price pressure
  - GSK still actively promoting Paxil CR™

It is very important to keep the sales effort behind Paxil CR™
John Coombe (GSK's CFO) Feb 2004

  - GSK aggressively defending last patent for Paxil® (expires end-2006)
- **Paxil® CR US sales:**
  - 2002: ~$300 mn
  - 2003: ~$650 mn
  - 2004: ~$800 mn (est – likely peak)
- **SkyePharma royalty rate: low single digits**
  - possible increase from start of US generic competition



Xatral® OD/Uroxatral® Sanofi-Synthélabo



Once-daily Geomatrix™ formulation of alfusozin

- uroselective alpha-blocker
- indication: urinary symptoms of BPH

On market in Europe & ROW since 2000

- replacing multidose versions

USA: Uroxatral®

- new product on US market
- launch to urologists Nov '03
- launch to primary care Mar '04
- two USPs:
  - uroselection (no postural hypotension)
  - no ejaculatory side-effects

Second indication: acute urinary retention (approved Europe; Ph III US)

2003 world sales €222 mn (+25% CER)

2006 forecast: €500 mn (*Sanofi-Synthélabo*)

SkyePharma royalty rate: mid-single digits



Three key near-term pipeline products

DepoMorphine™

Foradil® Certihaler™

Propofol IDD-D™

SkyePharma

DepoMorphine™ Endo, SkyePharma

Sustained-release morphine for relief of pain after surgery

- given as a single epidural injection before/during operation
- morphine released evenly over 48 hours (period of peak post-op. pain)
  - minimizes breakthrough pain
  - with conventional PCA, patient must react to pain
- no need for catheters and infusion pumps (= savings for hospital)

Disadvantages of conventional morphine

- effective analgesic – but short-acting
- repeat doses need a catheter and an infusion pump
- catheter problems main barrier to wider use of **epidural** analgesia
- epidural route desirable (delivers direct to brain, needs less morphine than IV)

Clinical trials (~1000 patients) highly statistically significant

- hip/knee surgery, lower abdominal surgery, caesarean section

US: **filed with FDA Jul '03** (***PDUFA date 18 May '04***)

Europe: **filed Nov '03** (***UK, then mutual recognition procedure***)

DepoMorphine™ - potential market

- knee replacements & revisions
- hip replacements & revisions
- major abdominal surgery
- cesarean sections
- thoracic
- vascular

- **~12 million** key target surgeries a year across the US and major Europe
- surgeries associated with an ageing population are **growing at 6-7% per annum**
- market research indicates potential for **25% - 40% patient share** in major territories. Assumes pricing equivalent to IV PCA or epidural infusion **($125 per surgical procedure)**
- est. sales potential: $250m
- exploring scope for **premium pricing**

DepoMorphine™ - Endo deal endorsed potential

$120m deal (Dec '02)

- US/Canada rights for **DepoMorphine™** and **Propofol IDD-D™**
- option on related pipeline products including **DepoBupivacaine**

Deal terms:

- $25 million upfront payment
- SkyePharma's share of sales **20-60%** on combined sales volume of DepoMorphine™ and Propofol IDD-D™
  - >50% share if combined sales >$250 mn

Rights for rest of world still available for licence

- European rights to be licensed early '04

Foradil®

Novartis / Schering Plough

Active ingredient formoterol

- fast-onset, long-acting bronchodilator for asthma
- recent major study on maintenance use of formoterol raises value
- SkyePharma developed both Certihaler™ **device** and **formulation**
  - formulation keeps powder dry, ensures accurate consistent dose
  - now also being used in second collaboration with Novartis (**QAB149**)

Schering-Plough to market in key US market, Novartis elsewhere

Filed US & Europe Dec ‘02 (launches expected in H2 ‘04)

- FDA “approvable” letter issued Oct ’03
- first European approval (Switzerland) Feb ‘04

SkyePharma return on sales: ~10% (royalty + manufacturing return)

Propofol IDD-D™ Endo, SkyePharma

- improved version of AstraZeneca's injectable anaesthetic *Diprivan*
- SkyePharma's formulation unique - cannot support microbial growth
  - no need for a preservative
  - 2% emulsion (= lower injection volume and less lipid)
  - **not a generic**
- designed for <u>continuous uninterrupted 24-hour sedation</u>
  - ICU sedation is fastest-growing segment of *Diprivan* market
- Ph III to start Q1'04; target filing: 2005; target launch: 2006
- **North America**: Endo (same terms as DepoMorphine™)
- **Europe/Japan**: licensees to be appointed
- est. sales potential for Propofol IDD-D™: $200 mn

Other major pipeline products

HFA-formoterol (SkyePharma)

- Fast onset, long-acting bronchodilator in HFA metered-dose inhaler (HFA-MDI)
- Value enhanced by recent major study on maintenance use of formoterol
- Ph II trial complete – Ph III to commence 2004
- Filing end 2005; launch 2006/7

Pulmicort® HFA-MDI (AstraZeneca for Europe)

- Pulmicort® (budesonide) inhaled steroid (for asthma)
- Ph II study complete - bioequivalent to CFC MDI
- Ph III trial ongoing
- Filing early 2005

DepoBupivacaine (SkyePharma)

- Long-acting injectable formulation of local anaesthetic
- Designed to provide 48-72 hours of local pain relief after out-patient surgery
- Target indications: knee arthroscopy; laparoscopic surgery; plastic surgery
- Ph I trial started in Europe Sep ’03; Ph II to start mid-2004

Requip® (GlaxoSmithKline)

- Once-daily oral formulation of ropinirole (for Parkinson’s disease)
- Therapeutic benefits + improved compliance
- SkyePharma managing clinical studies for GSK
- Ph III started Jun ‘03
- Filing 2005

2003 - new corporate developments

- licensing agreement signed with **King** for **Altace®** (ramipril)
  - leading branded ACE inhibitor with US$527 mn sales in 2003
- option agreement with **unnamed** partner in **pulmonary** area
- agreement with **Critical Therapeutics** to develop **zileuton** for asthma/COPD
  - once-daily version previously developed for Abbott
  - completed Phase III for asthma but never filed
- agreement with **Novartis** to co-develop **QAB149**
  - ultra-long acting bronchodilator for asthma/COPD
- agreement with **GlaxoSmithKline** to use **pulmonary** formulation technology
- **Astralis** commenced US Phase I clinical trial for **Psoraxine™** for psoriasis
- strategic stake in **Micap** plc – UK yeast technology specialist
  - successfully completed IPO on AIM Aug '03
  - SkyePharma exercised option over pharma applications Feb '04
- strategic stake in **Vital Living** Inc.
  - development of pharmaceutical-grade nutriceuticals

Well-stocked pipeline



Newsflow 2003 – most targets met

Filings

DepoMorphine™ US ✓

DepoMorphine™ Europe ✓

Paxil® CR Social Anxiety – *FDA approval 17 Oct*

Paxil® CR PMDD intermittent ✓

(Paxil® CR PMDD continuous – *FDA approval 2 Sep)*

Corporate & commercial agreements

European licensing of DepoMorphine™

European licensing of Propofol IDD-D™

European licensing of DepoCyte® ✓

Licensing of Pulmonary products

Licensing of Dermatology products

Licensing deal with King – Altace® ✓

Micap floated on AIM ✓

Product approvals/launches

Uroxatral® US ✓

DepoCyte® Europe

Foradil® Certihaler™ US *"approvable" 22 Oct*

Clinical trial progression

Requip®	Ph III start ✓
Propofol IDD-D™	Ph II end ✓
Propofol IDD-D™	Ph III start
Pulmicort® HFA-MDI	Ph III start ✓
Psoraxine™ (Astralis)	Ph I start ✓

Clinical data publications

DepoMorphine™ Ph III

Foradil® DPI Ph III

Uroxatral® Ph III

Newsflow 2004 – further progress

Filings

Pulmicort® HFA-MDI Europe

Requip® OD Europe (US 2005)

Licence agreements

DepoMorphine™ (Europe)

Pulmonary product package

Unnamed pipeline product

Dermatology products

Propofol IDD-D™ (Europe)

DepoBupivacaine™ (Europe)

Clinical data publications (by partners)

DepoMorphine™ Ph III

Foradil® Certihaler™ Ph III

Uroxatral® Ph III

Product approvals/launches

Paxil® CR PMDD intermittent US	✓
DepoMorphine™ US	*PDUFA date 18 May*
Launch of DepoCyte® Europe	✓
Foradil® Certihaler™ US	*"approvable" Oct '03*
Foradil® Certihaler™ Europe	✓

Clinical trial progression

Propofol IDD-D™	Ph III start
Formoterol HFA-MDI	Ph III start
Formoterol+fluticasone HFA-MDI	Ph II/III start
Zileuton (Critical Therapeutics)	Ph III start (COPD)
Psoraxine™ (Astralis)	Ph II start
DepoBupivacaine™	Ph II start

Investment highlights

Evolved from a **technology** focus to a **product** development focus

Nine approved products validate drug delivery technologies

Changing **quality of earnings** driven by royalties from **Paxil CR™, Xatral® OD/Uroxatral®, Solaraze™, DepoCyt®**

- with **Foradil® Certihaler™, DepoMorphine™, HFA-formoterol & Propofol IDD-D™** close behind

Strong **near-term clinical pipeline**

2 Filed, 4 x Phase III, 3 x Phase II

Royalty growth to drive move to sustained and rising **profitability**

SkyePharma

making good drugs better

Investor relations contacts:

London

Peter Laing, Director of Corporate Communications

44-(0)207-491-1777 plaing@skyepharma.co.uk

New York

Sandra Haughton, US Investor Relations Manager

1-212-753-5780 shaughton@skyepharma.com

…and please visit our website

NASDAQ:SKYE LSE:SKP

www.skyepharma.com